SCHEMBL4907304

SCHEMBL4907304

CC(C)NS(=O)(=O)c1ccc2c(c1)C(=NNc1ccccc1C(N)=O)C(=O)N2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.40
CDK2 P24941 1/20 0.40
ALDH1A1 P00352 4/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
PTPN11 Q06124 4/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CA1 P00915 5/20 0.36
CA2 P00918 5/20 0.36
CA12 O43570 4/20 0.36
CA9 Q16790 4/20 0.36
MGAT1 P26572 1/20 0.36
MGAT2 Q10469 1/20 0.36
NPSR1 Q6W5P4 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907302 1.00 KDR (0.40) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4903828 0.91 PTPN11 (0.43) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4903823 0.91 PTPN11 (0.43) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4903841 0.91 CDK2 (0.40) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4903838 0.91 CDK2 (0.40) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4904950 0.89 CDK2 (0.39) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4904943 0.89 CDK2 (0.39) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4908785 0.88 CDK2 (0.39) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4908777 0.88 CDK2 (0.39) KDRCDK2ALDH1A1LMNAMAPT
SCHEMBL4906515 0.86 KDM4E (0.43) KDRCDK2ALDH1A1PTPN11KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987474-B2 Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs UNIVERSITY OF SOUTH FLORIDA (US) 2015-03-24 US disclosed
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer UNIVERSITY OF SOUTH FLORIDA (US) 2008-07-24 US disclosed
WO-2007117699-A2 INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS UNIVERSITY OF SOUTH FLORIDA (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer PTPN7, PTPN1, PTPN2 KDR 355/4885CDK2 541/4885ALDH1A1 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.